Inhalation Sciences AB subsidiary Ziccum releases antibody data from successful proof-of-concept test

Used to treat a wide range of diseases, approx. 450 human antibodies are currently being developed—but many are formulated as liquids, risking instability and attrition in clinical trials. Ziccum AB now releases full data from its recent successful proof-of-concept test, showing how LaminarPace dried human antibodies into stable, active dry powders. The data include SEM (Scanning Electron Microscope) images, and more.

Ziccum's spray drying tool LaminarPace has successfully dried proteins before, but this was its first test specifically on antibodies. Ziccum AB CEO Göran Conradson: "This is a resounding proof of concept for LaminarPace. Being able to dry antibodies hugely increases their accessibility whilst keeping them biologically active. It confirms that LaminarPace can help research, pharma and healthcare organizations everywhere reach new findings and markets."

The new data from proof-of-concept test can be downloaded **HERE**. They include SEM images, Yield, particle size distribution and turbidimetry on precipitation. The tests dried three samples at room temperature, achieving high yields. 25.54 mg of dry powder IgG was gathered from 2 mL, a yield of 84.7%. The antibodies remained active after being dried.

Ziccum AB, an ISAB subsidiary, has recently attracted capital funding of 2 MSEK. Ziccum expects to be listed independently in Q4 2018. Its flagship product, LaminarPace, dries biologics, vaccines, drug substances and chemicals at room temperature—transforming often delicate, difficult-to-transport liquids, into stable, effective dry powders that require no refrigeration or cold storage.

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.